Trial Outcomes & Findings for Clinical Comparison of Femoral Nerve Versus Adductor Canal Block Following Anterior Ligament Reconstruction (NCT NCT03704376)

NCT ID: NCT03704376

Last Updated: 2021-10-21

Results Overview

Quadriceps muscle activation was examined using surface electromyography (sEMG) of the vastus medialis oblique muscle. Peak sEMG activity was recorded in microvolts (uV) on the surgical and contralateral limbs while performing five maximal effort isometric contractions in full knee extension--the reported values are equal to the quadriceps sEMG in uV of the contralateral limb minus the quadriceps sEMG in uV of the surgical limb.

• Recruitment status: COMPLETED
• Study phase: PHASE4
• Target enrollment: 125 participants
• Primary outcome timeframe: Post-operative day 1
• Results posted on: 2021-10-21

Participant Flow

125 were enrolled, but 39 were excluded because they ended up receiving a different type of graft.

Participant milestones

Measure	Femoral Nerve Blockade Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Overall Study STARTED	42	44
Overall Study COMPLETED	38	40
Overall Study NOT COMPLETED	4	4

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Total n=78 Participants Total of all reporting groups
Age, Continuous	24.4 years STANDARD_DEVIATION 8.8 • n=38 Participants	21.0 years STANDARD_DEVIATION 7.3 • n=40 Participants	22.7 years STANDARD_DEVIATION 8.1 • n=78 Participants
Sex: Female, Male Female	18 Participants n=38 Participants	17 Participants n=40 Participants	35 Participants n=78 Participants
Sex: Female, Male Male	20 Participants n=38 Participants	23 Participants n=40 Participants	43 Participants n=78 Participants
Race and Ethnicity Not Collected	—	—	0 Participants Race and Ethnicity were not collected from any participant.
Region of Enrollment United States	38 Participants n=38 Participants	40 Participants n=40 Participants	78 Participants n=78 Participants

PRIMARY outcome

Timeframe: Post-operative day 1

Quadriceps muscle activation was examined using surface electromyography (sEMG) of the vastus medialis oblique muscle. Peak sEMG activity was recorded in microvolts (uV) on the surgical and contralateral limbs while performing five maximal effort isometric contractions in full knee extension--the reported values are equal to the quadriceps sEMG in uV of the contralateral limb minus the quadriceps sEMG in uV of the surgical limb.

Outcome measures

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Quadriceps Muscle Activation as Assessed by Surface Electromyography (sEMG)	266.5 microvolts (uV) Standard Deviation 52.4	212.5 microvolts (uV) Standard Deviation 65.1

PRIMARY outcome

Timeframe: Post-operative day 14

Quadriceps muscle activation was examined using surface electromyography (sEMG) of the vastus medialis oblique muscle. Peak sEMG activity was recorded in microvolts (uV) on the surgical and contralateral limbs while performing five maximal effort isometric contractions in full knee extension--the reported values are equal to the quadriceps sEMG in uV of the contralateral limb minus the quadriceps sEMG in uV of the surgical limb.

Outcome measures

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Quadriceps Muscle Activation as Assessed by Surface Electromyography (EMG)	183.2 microvolts (uV) Standard Deviation 41.8	126.5 microvolts (uV) Standard Deviation 48.9

PRIMARY outcome

Timeframe: 4 weeks post operative

Quadriceps muscle activation was examined using surface electromyography (sEMG) of the vastus medialis oblique muscle. Peak sEMG activity was recorded in microvolts (uV) on the surgical and contralateral limbs while performing five maximal effort isometric contractions in full knee extension--the reported values are equal to the quadriceps sEMG in uV of the contralateral limb minus the quadriceps sEMG in uV of the surgical limb.

Outcome measures

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Quadriceps Muscle Activation as Assessed by Surface Electromyography (EMG)	109.1 microvolts (uV) Standard Deviation 32.2	94.1 microvolts (uV) Standard Deviation 33.2

SECONDARY outcome

Timeframe: Post-operative day 1

The straight leg raise assessment was performed in a standardized long-sitting position with well-knee flexed to 90 degrees. Patients were asked to complete 30 repetitions of straight leg raises with a small bolster supporting the heel using the following criteria; (1) perform with no visible quad lag (2) reach the height of the opposite tibial tubercle and (3) maintain a controlled rate of 30 hertz for the ascending and descending phases. The examination was only performed on the surgical limb and the absolute number of successful repetitions is reported.

Outcome measures

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Number of Successful Repetitions With Straight Leg Raise Test	3.2 number of repetitions Standard Deviation 6.1	6.2 number of repetitions Standard Deviation 8.0

SECONDARY outcome

Timeframe: Post-operative day 14

The straight leg raise assessment was performed in a standardized long-sitting position with well-knee flexed to 90 degrees. Patients were asked to complete 30 repetitions of straight leg raises with a small bolster supporting the heel using the following criteria; (1) perform with no visible quad lag (2) reach the height of the opposite tibial tubercle and (3) maintain a controlled rate of 30 hertz for the ascending and descending phases. The examination was only performed on the surgical limb and the absolute number of successful repetitions is reported.

Outcome measures

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Number of Successful Repetitions With Straight Leg Raise Test	23.3 number of repetitions Standard Deviation 10.6	24.2 number of repetitions Standard Deviation 10.9

SECONDARY outcome

Timeframe: 4 weeks post operative

The straight leg raise assessment was performed in a standardized long-sitting position with well-knee flexed to 90 degrees. Patients were asked to complete 30 repetitions of straight leg raises with a small bolster supporting the heel using the following criteria; (1) perform with no visible quad lag (2) reach the height of the opposite tibial tubercle and (3) maintain a controlled rate of 30 hertz for the ascending and descending phases. The examination was only performed on the surgical limb and the absolute number of successful repetitions is reported.

Outcome measures

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Number of Successful Repetitions With Straight Leg Raise Test	29.7 number of repetitions Standard Deviation 1.4	30 number of repetitions Standard Deviation 0.0

SECONDARY outcome

Timeframe: 1 hr post surgery

The items are scored on a visual analogical scale from 0-10, 0 being the better outcome.

Outcome measures

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Postoperative Pain Control as Assessed by a Numeric Pain Rating Scale	0.81 units on a scale Standard Deviation 2.09	0.8 units on a scale Standard Deviation 2.23

SECONDARY outcome

Timeframe: 2 hr post surgery

The items are scored on a visual analogical scale from 0-10, with 0 being the better outcome.

Outcome measures

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Postoperative Pain Control as Assessed by a Numeric Pain Rating Scale	1.78 units on a scale Standard Deviation 2.61	2.13 units on a scale Standard Deviation 3.2

SECONDARY outcome

Timeframe: 3 hr post surgery

The items are scored on a visual analogical scale from 0-10, with 0 being the better

Outcome measures

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Postoperative Pain Control as Assessed by a Numeric Pain Rating Scale	2.65 units on a scale Standard Deviation 2.8	3.23 units on a scale Standard Deviation 3.3

SECONDARY outcome

Timeframe: 4 hr post surgery

The items are scored on a visual analogical scale from 0-10, with 0 being the better outcome.

Outcome measures

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Postoperative Pain Control as Assessed by a Numeric Pain Rating Scale	2.83 units on a scale Standard Deviation 2.6	2.87 units on a scale Standard Deviation 3.08

SECONDARY outcome

Timeframe: 5 hr post surgery

The items are scored on a visual analogical scale from 0-10, with 0 being the better outcome.

Outcome measures

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Postoperative Pain Control as Assessed by a Numeric Pain Rating Scale	2.97 units on a scale Standard Deviation 2.47	3.06 units on a scale Standard Deviation 2.94

SECONDARY outcome

Timeframe: 6 hr post surgery

The items are scored on a visual analogical scale from 0-10, with 0 being the better outcome.

Outcome measures

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Postoperative Pain Control as Assessed by a Numeric Pain Rating Scale	2.63 units on a scale Standard Deviation 2.51	3.03 units on a scale Standard Deviation 2.99

SECONDARY outcome

Timeframe: 7 hr post surgery

The items are scored on a visual analogical scale from 0-10, with 0 being the better outcome.

Outcome measures

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Postoperative Pain Control as Assessed by a Numeric Pain Rating Scale	2.83 units on a scale Standard Deviation 2.22	2.81 units on a scale Standard Deviation 2.63

SECONDARY outcome

Timeframe: 8 hr post surgery

The items are scored on a visual analogical scale from 0-10, with 0 being the better outcome.

Outcome measures

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Postoperative Pain Control as Assessed by a Numeric Pain Rating Scale	2.84 units on a scale Standard Deviation 2.04	2.57 units on a scale Standard Deviation 2.63

SECONDARY outcome

Timeframe: 9 hr post surgery

The items are scored on a visual analogical scale from 0-10, with 0 being the better outcome.

Outcome measures

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Postoperative Pain Control as Assessed by a Numeric Pain Rating Scale	2.91 units on a scale Standard Deviation 2.07	2.41 units on a scale Standard Deviation 2.27

SECONDARY outcome

Timeframe: 10 hr post surgery

The items are scored on a visual analogical scale from 0-10, with 0 being the better outcome.

Outcome measures

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Postoperative Pain Control as Assessed by a Numeric Pain Rating Scale	2 units on a scale Standard Deviation 1.9	2.53 units on a scale Standard Deviation 1.89

SECONDARY outcome

Timeframe: 11 hr post surgery

Population: No participants were analyzed for this time point because participants were discharged from hospital at around 10 hours, before this time point would have occurred.

The items are scored on a visual analogical scale from 0-10, with 0 being the better outcome.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 12 hr post surgery

Population: No participants were analyzed for this time point because participants were discharged from hospital at around 10 hours, before this time point would have occurred.

The items are scored on a visual analogical scale from 0-10, with 0 being the better outcome.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Postoperative physicians visit

Population: Patients were not analyzed at postoperative physicians visit.

The items are scored on a visual analogical scale from 0-10, with 0 being the better

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Entire post-anesthesia care unit (PACU) visit post surgery, PACU range 1 hr to 12 hrs post surgery

morphine equivalents consumed during the entire post-anesthesia care unit (PACU) visit post surgery will be obtained from the All-scripts electronic medical record (EMR) system.

Outcome measures

Measure	Femoral Nerve Blockade n=38 Participants Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 Participants Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Narcotics Use as Assessed by Morphine Equivalents Consumed	14.8 milligrams (mg) Standard Deviation 8.3	16.0 milligrams (mg) Standard Deviation 7.4

Adverse Events

Femoral Nerve Blockade

Serious events: 0 serious events

Other events: 16 other events

Deaths: 0 deaths

Adductor Canal Blockade

Serious events: 0 serious events

Other events: 11 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Measure	Femoral Nerve Blockade n=38 participants at risk Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation. 30 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer	Adductor Canal Blockade n=40 participants at risk Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ). 15 ml of 0.2% ropivacaine 100 mcg clonidine High-frequency linear ultrasound transducer
Musculoskeletal and connective tissue disorders Anterior Knee Pain	18.4% 7/38 • Number of events 7 • 6 months	20.0% 8/40 • Number of events 8 • 6 months
Musculoskeletal and connective tissue disorders Knee Extension Loss	21.1% 8/38 • Number of events 8 • 6 months	5.0% 2/40 • Number of events 2 • 6 months
Vascular disorders Deep Vein Thrombosis	0.00% 0/38 • 6 months	2.5% 1/40 • Number of events 1 • 6 months
Musculoskeletal and connective tissue disorders Reinjury	2.6% 1/38 • Number of events 1 • 6 months	0.00% 0/40 • 6 months

Additional Information

Lane Bailey, PhD, PT

The University of Texas Health Science Center at Houston

Phone: 713-704-6794

Email: lane.bailey@uth.tmc.edu

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place